The honest case against life-insurance-linked assets

No asset class deserves to be evaluated only by its proponents, and life-insurance-linked investing is not an exception. This article is an attempt to lay out, as fairly as I can, the strongest honest case against the category, and then to offer a response that does not pretend the risks are smaller than they actually are.

The article is structured in two halves of roughly equal length. The first half makes the case against. The second half responds to each objection in turn. Where I think the case against is strong, I say so. Where I think the response is partial rather than complete, I say that too. The goal is intellectual honesty, not advocacy.

This article assumes some familiarity with the asset category. Readers new to the topic may want to start with our introduction at A family office introduction to life-insurance-linked assets and then return.

Part one: the case against, in its strongest form

Longevity risk

Longevity risk is the most important risk in life-insurance-linked investing, and any honest case against begins here. If the insureds in a portfolio of life settlements live materially longer than the modeled life expectancies, the buyer pays more premiums over a longer period before the death benefits arrive. Returns compress, sometimes materially. The asset class has a real history of longevity-related underperformance, including episodes in the late 2000s and early 2010s during which industry-wide actual mortality experience exceeded modeled expectations. Critics point to those episodes as evidence that the asset class is structurally exposed to the systematic risk of medical progress: if new therapies extend life expectancies in ways that the actuarial models did not anticipate, every portfolio in the asset class loses value at once.

This risk is real. It is the single biggest reason for prudent investors to size positions modestly relative to total portfolio capital. The Actuarial Standards Board's ASOP 48, which governs mortality assumption work in life settlements, exists precisely because the history of the industry has included episodes in which modeled and realized mortality diverged.

Liquidity and long lock-ups

Life-insurance-linked assets are illiquid. Life settlements in particular require holding periods measured in years. Institutional funds typically impose lock-up periods, redemption gates, and notice periods that reflect the underlying duration of the assets. An investor who needs capital before the natural maturity profile of the portfolio is not in a good position to extract it. Forced selling in a secondary market exists but tends to price at meaningful discounts to modeled value, particularly in stressed conditions.

This is not a fixable feature of the category. The duration of the assets is the duration of the assets. Investors who need liquidity should not own these strategies in size.

Complexity and opacity

The asset class is more complex than public equity or fixed income, and harder to evaluate from the outside. Understanding what a portfolio actually owns requires reading policy documents, understanding actuarial conventions, evaluating life expectancy methodology, and assessing carrier credit. A passive allocator who wants to make a decision in an hour cannot do so responsibly here. Even sophisticated allocators sometimes underestimate the depth of diligence required.

Marked valuations in particular involve methodological choices that are not always transparent. Discount-rate assumptions, mortality assumptions, premium projection methodology, and policy-by-policy carrier credit treatment can all be set in ways that produce materially different valuations from the same underlying portfolio. The combination of long duration and methodological discretion creates room for valuation error, accidental or otherwise.

Tax complexity and K-1 reporting

Most institutional vehicles in the category are structured as partnerships that issue Schedule K-1 forms to investors rather than the Form 1099 that mutual funds and corporate dividend payers use. K-1s arrive later in the tax year than 1099s. They can introduce state filing obligations in jurisdictions where the underlying assets are situated. They can interact with unrelated business taxable income (UBTI) rules in unhelpful ways for some tax-exempt investors, which is why many such investors require offshore feeder or corporate blocker structures. The tax complexity is a real friction.

Carrier credit concentration

Every dollar of death benefit ultimately comes from an insurance carrier. If the carrier becomes insolvent, the obligation is not extinguished — state guaranty associations provide statutory backstops up to specified limits — but recovery can be delayed and reduced. Concentrating policies on a small number of carriers creates a credit exposure that is structurally long-duration and difficult to hedge. The asset class, in aggregate, is taking long-duration credit exposure to the life insurance industry.

Model risk

Pricing and valuing a life settlement depends on actuarial models. Actuarial models are the best available tools for the job, but they are still models. The mortality distribution for any given individual is uncertain, and the LE report a buyer relies on is an estimate, not a prediction. Aggregated across a portfolio, modeling error tends to average out, but it does not disappear. The history of the industry includes periods in which industry-wide LE methodology proved to be systematically biased, with the result that every portfolio underwritten on that methodology saw correlated revisions.

Operational and service-provider dependence

Running a life settlement portfolio at institutional scale depends on a chain of service providers: fund administration, custody, premium servicing, policy tracking, third-party valuation, audit, and tax preparation. A failure anywhere along this chain can affect the portfolio. Compared with public market alternatives, the asset class is operationally heavier. The dependencies are manageable but not trivial.

The ethical objection

Some investors will refuse to hold mortality-linked assets on principle. The discomfort is not, in our view, well-supported by the actual economics of the asset class (the argument is laid out in our article on the ESG case for life settlements at The ESG case for life settlements). But the discomfort is real, and the choice to avoid the asset class on principle deserves respect. For an investor who feels this way strongly, no amount of economic argument will resolve the objection, nor should it.

Suitability

The category is not suitable for investors who need liquidity, cannot tolerate K-1 reporting complexity, are uncomfortable with multi-year holding periods, or are not in a position to do the diligence the asset class requires. The asset class is genuinely demanding to evaluate properly, and shortcuts do not typically end well.

The arbitrage framing as a critique

There is a more sophisticated critique that sometimes circulates among careful observers of the asset class. The framing is that life settlement returns are, in effect, an arbitrage between policyholder-side surrender values and institutional-buyer-side actuarial pricing, and that any such arbitrage must eventually compress as the market matures. Critics point to historical episodes of yield compression and conclude that the asset class is a wasting opportunity. This is a serious view held by sophisticated investors.

Part two: the honest response

Each of the objections above deserves a careful response. The aim here is not to dissolve the objections but to describe what disciplined practice in the asset class actually does about them. None of the responses claim that the underlying risk is eliminated.

On longevity risk

Longevity risk is real and is not eliminated. It is managed through several disciplines that together reduce, without removing, the exposure. Diversification across many insureds reduces the variance around the central mortality expectation by the law of large numbers. Diversification across age, sex, medical profile, carrier, and policy structure prevents the portfolio from being concentrated against a single underlying risk vector. Conservative bidding — declining policies whose pricing requires aggressive mortality assumptions — leaves headroom for adverse experience. Continuous model refinement, drawing on realized portfolio experience as it accumulates, reduces the chance that an outdated methodology persists undetected.

The honest version of the response is that longevity risk is the central risk of the asset class and the central reason for position sizing discipline. We do not believe it can be hedged out; we believe it can be diversified, monitored, and priced conservatively. Investors who are uncomfortable with this kind of fundamental risk should not own the asset class in size.

On liquidity and lock-ups

Illiquidity is a feature, not a bug. The category exists because long-duration capital is willing to commit to long-duration assets, and the compensation for that commitment is part of what produces the return. The structural advantage that compensates the investor is, in effect, the absence of forced selling in the holding profile most natural to the asset class. An investor who can match the duration of the asset to a multi-year hold can ride through periods of stressed secondary-market pricing rather than being forced to realize losses at those prices.

The honest version of the response is that liquidity risk is not something the asset class manages — it is something the investor manages, by matching position size to their actual ability to tolerate illiquidity. A family office with patient capital can hold these assets through any environment; an investor who might need to liquidate cannot.

On complexity and opacity

Complexity is real, and it is the structural barrier to entry that creates much of the return opportunity. If the asset class were easy to understand, it would likely be more crowded and less rewarding. The honest response is that the complexity should be embraced as an explicit cost of the category: investors should expect to spend more diligence time per dollar allocated, retain advisors who understand the area, and engage with managers willing to answer detailed questions.

On the opacity of valuation methodology, the discipline is to insist on independent third-party valuation, transparent documentation of methodology, and audit by a recognized accounting firm. None of these eliminate methodological discretion, but together they bound it.

On tax complexity and K-1 reporting

The tax complexity is real. K-1s are more involved than 1099s; state filings can multiply; UBTI considerations apply for some tax-exempt investors. The honest response is that this is part of the cost of operating in the category, and that investors should plan for it: extensions are common, blocker structures are available for investors who need them, and tax advisors with experience in alternative partnerships can usually integrate the reporting into a broader filing strategy without unreasonable friction. None of these mitigate the complexity itself; they make it workable.

On carrier credit concentration

Carrier credit risk is structurally long-duration and difficult to hedge. The discipline is to diversify across many highly-rated carriers, to monitor carrier credit quality continuously through ratings from A.M. Best, Standard & Poor's, Moody's, and Fitch, and to be aware of the statutory backstop provided by state guaranty associations. None of these eliminate the exposure. They contain it.

It is worth noting that, in practice, the life insurance industry has been one of the more financially stable corners of the broader financial sector through the cycles of the past several decades. State-level solvency regulation, capital requirements, and the structure of life insurance liabilities have made carrier failures historically rare. This is not a guarantee against future failures; it is context for sizing the exposure.

On model risk

Model risk cannot be eliminated, but it can be managed through several practices. Maintaining multiple independent LE reports per policy reduces the dependence on any single underwriting firm. Building an in-house mortality view that can be compared against external reports creates a discrepancy-detection mechanism. Continuous calibration of model output against realized portfolio experience as it accumulates allows methodology to be updated rather than fossilized. Honest disclosure of the limits of the modeling — both internally and to investors — keeps the system from drifting toward overconfidence.

A fuller treatment of how machine learning fits into this picture, and where the technology is and is not yet earning its place, appears in our companion article "Where AI is actually changing underwriting — and where it's marketing" at Where AI is actually changing underwriting — and where it's marketing.

On operational dependence

Operational dependence is managed by selecting service providers carefully, requiring strong controls and audit, and maintaining redundancy where possible. The category has matured to the point that the standard set of fund administrators, custodians, valuation agents, premium servicing firms, and auditors capable of handling the asset class is well-established. The honest response is that operational risk is more contained today than it was in the formative years of the industry, but it is not zero.

On the ethical objection

We have addressed this at length in our companion article on the ESG case for life settlements at The ESG case for life settlements. The short version: the seller is better off; the investor provides liquidity at fair market value for an asset the policyholder no longer wants; the timing of the mortality event is determined by factors entirely outside any investor's influence. We believe the case in favor is strong; we also believe that investors who feel discomfort on principle should be free to honor that discomfort. Not every investor's ethical framework is reducible to economic argument.

On suitability

The honest response on suitability is simply to repeat what is true: the asset class is not for everyone, and the right reaction to that is to size accordingly or decline. Investors with shorter horizons, less complex back offices, or lower tolerance for opacity should weight the category lightly or not at all. The asset class works for the investors it works for; it is not a universal answer.

On the arbitrage framing

We think the arbitrage critique misframes the economics. There is no risk-free arbitrage in this market. There is compensated risk transfer: the buyer takes on longevity uncertainty, premium-projection uncertainty, carrier credit exposure, and illiquidity in exchange for an expected return. The compensation is for accepting these risks, not for exploiting a pricing error. If the market matures further, the spread between expected return and the risk-free rate can certainly compress; the compensation for risk transfer can move with broader market conditions. But the underlying economic structure — risk transfer, pooling at scale, time value of capital — is not an arbitrage that disappears when discovered. It is a return for bearing risk, which is the same structural source of return as any other compensated risk premium.

A more detailed treatment of how to evaluate uncorrelated-asset claims generally, including how life-insurance-linked assets stand up to the framework, appears in our companion article "Stress-testing 'uncorrelated': what we look for before calling an asset truly diversifying" at Stress-testing 'uncorrelated': what we look for before calling an asset truly diversifying.

The structural advantages that survive the critique

Once each objection has been considered honestly, a small number of structural features of the asset class survive the analysis and constitute the actual case for inclusion in a portfolio.

First, the underlying risk factor is genuinely distinct. Mortality timing is not driven by interest rates, equity markets, credit spreads, or any of the other macroeconomic variables that drive most of a typical portfolio. The structural source of diversification is unusually clean.

Second, the principal cash flows are contractual obligations of regulated counterparties. The death benefit on a life insurance policy is a contract with an insurance carrier subject to state insurance department oversight, capital requirements, and rating agency scrutiny. The cash flow is not subject to the default behavior of, say, a corporate bond.

Third, returns are realized through actual cash distributions over time rather than through reliance on mark-to-market revaluation. This is a different and arguably more robust source of return than mark-to-market alternatives, particularly for investors who can match holding periods to asset duration.

Fourth, the regulatory framework is mature. Compared with many alternative asset categories, life settlements operate within an unusually thorough statutory framework built on NAIC and NCOIL model acts, state licensing, mandatory disclosures, fiduciary duties for brokers, and Actuarial Standards Board guidance for the underlying actuarial work.

None of these structural advantages reduces the risks identified in part one of this article. They are reasons the asset class can be worth owning despite those risks, for the right investor.

A short closing

This asset class is not for everyone, and that is appropriate. The risks are real; the suitability constraints are real; the complexity is real; and the ethical objection deserves respect even when an economic argument can be made against it. For an investor who needs liquidity, prefers simplicity, or holds an objection on principle, the right answer is to allocate elsewhere.

For an investor with long-horizon capital, comfort with complexity, the ability to engage with the diligence the category requires, and no overriding ethical objection, the structural advantages outlined in part two can make the asset class a defensible component of a diversified portfolio. The right way to enter is with eyes open about the case against, modest position sizing, careful diligence, and the recognition that no amount of disciplined practice eliminates the underlying risks the category requires the investor to accept.

If you would like a fuller introduction to the asset category, see our overview at A family office introduction to life-insurance-linked assets. If you would like to engage with the ethical question in depth, see The ESG case for life settlements. If you would like the underwriting and technology view, see Where AI is actually changing underwriting — and where it's marketing. And if you would like a fuller treatment of how the category stands up to scrutiny of its uncorrelation claims, see Stress-testing 'uncorrelated': what we look for before calling an asset truly diversifying.